TCGA-GV-A3QG-01A-11R-A220-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.590
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.530
- INTERFERON_GAMMA_RESPONSE+0.530
- INTERFERON_ALPHA_RESPONSE+0.510
- IL6_JAK_STAT3_SIGNALING+0.500
- ANGIOGENESIS+0.490
- INFLAMMATORY_RESPONSE+0.470
- COMPLEMENT+0.460
- IL2_STAT5_SIGNALING+0.410
- UV_RESPONSE_DN+0.350
Top 10 suppressed
- MYC_TARGETS_V2-0.480
- OXIDATIVE_PHOSPHORYLATION-0.460
- DNA_REPAIR-0.220
- MYC_TARGETS_V1-0.220
- P53_PATHWAY-0.130
- PEROXISOME-0.130
- ESTROGEN_RESPONSE_LATE-0.120
- GLYCOLYSIS-0.100
- ADIPOGENESIS-0.060
- KRAS_SIGNALING_DN-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-DK-A3IU-01A-11R-A20F-07 | — | — | 0.927 |
| 2 | TCGA-FD-A3B8-01A-31R-A20F-07 | — | — | 0.924 |
| 3 | TCGA-CV-7090-01A-11R-2016-07 | — | — | 0.912 |
| 4 | c55bb20b-c929-42e2-be7f-8b1da7bee953 | — | — | 0.906 |
| 5 | SRR8613717 | — | D | 0.892 |
| 6 | c7a22797-676e-4f10-a51d-e3ee91a29a21 | — | — | 0.892 |
| 7 | TCGA-D8-A27M-01A-11R-A16F-07 | — | D | 0.887 |
| 8 | MDT-AP-2029 | Med | Medulloblastoma | 0.887 |
| 9 | MDT-AP-0390 | Med | Medulloblastoma | 0.884 |
| 10 | TCGA-BH-A0BL-01A-11R-A115-07 | — | D | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.590 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.530 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.530 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.510 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.500 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.490 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| COMPLEMENT | 0.460 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.410 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.310 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.280 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.260 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.240 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.240 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.230 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |